

**BC EMERGENCY HEALTH SERVICES
Board of Directors PUBLIC Meeting
Tuesday, May 13, 2025
8:00 am to 8:19 am**

MINUTES

BCEHS Board of Directors

Elizabeth Cull (Chair) Colleen Austin 'Wii Goot Jim Chu Doug LePard
Barry O'Neill

Executive and Leadership Team

Dr. Penny Ballem, Interim President and CEO, PHSA
Dr. Leanne Heppell, Executive Vice President, PHSA & Chief Ambulance Officer, BCEHS
Zulie Sachedina, General Counsel & Chief Legal Officer, PHSA
Jennie Helmer, Chief Operating Officer, BCEHS
Dr. Sandra Jenneson, Chief Medical Officer, BCEHS
Paul Vallely, Chief Quality, Planning and Coordination Officer, and Interim Chief Paramedic Practice, BCEHS
Kevin Smith, Chief Transformation & Strategy Officer, BCEHS
Annie Leung, Executive Assistant to the President and CEO, PHSA & BCEHS Board Liaison & Executive Administrator
Eva Chow, Board Administrator & Executive Assistant to EVP, PHSA & Chief Ambulance Officer, BCEHS (*recorder*)

Guests

Dr. Jim Christenson, Professor, UBC Department of Emergency Medicine, Co-Director, BC Resuscitation Research Collaborative, UBC

Regrets

Lauren Brown, BCEHS Board Director

1. Call to Order

Elizabeth Cull called the meeting to order.

2. Indigenous Welcome & Land Acknowledgement

Elizabeth Cull offered the land acknowledgement.
Colleen Austin 'Wii Goot provided the Indigenous welcome.

3. Agenda Approvals and Conflicts

- 3.1 Approval of the May 13, 2025, Meeting Agenda.
Moved by Doug LePard, seconded by Colleen Austin 'Wii Goot. Carried.
No conflicts were declared.

4. Approval of the March 11, Board of Directors Meeting Minutes

Moved by Doug LePard, seconded by Colleen Austin 'Wii Goot. Carried.

5. FRONTIER Trial

The Frontier Trial, presented by Dr. Jim Christenson, explored a new medication called Nerinetide which could help to protect the brain if given very early during a stroke—even before patients arrive at the hospital. The medication can be given by primary care paramedics in the ambulance, before patients arrive at the hospital. The trial included stroke patients within three hours of symptom onset in both British Columbia and Ontario hospitals. While the results did not show a major benefit

for all stroke patients, the drug did seem to help those with a common type of stroke called Ischemic stroke. These patients had better brain function afterward. The study also showed that it is possible to safely begin stroke treatment in the field, especially for those people in rural or remote areas. In the meantime, Nerinetide has not been approved in Canada yet, but another trial is now underway in Calgary and approval could come in the next one or two years.

6. Resolution to Convene Closed Session of the Meeting

Moved by Colleen Austin 'Wii Goot, seconded by Jim Chu. Carried.

CLOSED MEETING